CVS Health's forecast points to more pain at long-term care business

Image
Reuters
Last Updated : Feb 20 2019 | 8:55 PM IST

(Reuters) - CVS Health Corp blamed weakness in its long-term healthcare business for a shortfall in its full-year profit forecast, indicating more troubles at the unit it bought about four years ago.

The company's shares fell 7 percent as it also revealed a $2.2 billion goodwill impairment charge related to the business, which houses the Omnicare unit, in the fourth quarter, taking the total charges at the unit to more than $6 billion in the past year.

The Omnicare business, which the company bought for about $10 billion in 2015, provides prescription drugs to nursing homes and other long-term care centers. It has been hit by lower occupancy rates in skilled nursing facilities and reimbursement pressures in the past few quarters.

"The long-term care business has continued to experience industry wide challenges that have impacted our ability to grow the business at the rate that was originally estimated when the company acquired Omnicare," the company said in a statement.

CVS said the unit's final budget for 2019 showed a significant deterioration in its forecasts for 2019, resulting in further updates to its long-term forecast beyond 2019.

"We are taking comprehensive actions to move past them," Chief Executive Officer Larry Menlo said.

The company, which bought health insurer Aetna last year, forecast full-year 2019 adjusted profit of $6.68 per share to $6.88 per share, while analysts on average currently expect $7.41 per share, according to IBES data from Refinitiv.

Evercore ISI analysts said the main issues with the company appeared to be long-term care challenges, pharmacy reimbursement pressure, lower drug price rise and questions around rebates.

For the fourth quarter, CVS Health earned $2.14 per share excluding items, beating the average estimate of $2.05 per share.

Same-store sales at the company's pharmacies that sell prescription drugs rose 7.4 percent in the quarter, compared with an expected 6.1 percent rise forecast by analysts.

The company booked a net loss of $419 million in the fourth quarter ended Dec. 31, compared with a net income of $3.29 billion, a year earlier when it benefited from changes to U.S. tax laws.

Revenue rose to $54.42 billion in the quarter from $48.39 billion a year earlier.

(Reporting by Aakash Jagadeesh Babu and Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 20 2019 | 8:51 PM IST

Next Story